Literature DB >> 28225747

Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder.

Ayse Kutlu1, Ulku Akyol Ardic, Eyup Sabri Ercan.   

Abstract

BACKGROUND AND AIM: Emotional dysregulation (ED) is a frequent feature of attention-deficit/hyperactivity disorder (ADHD). It can be observed as a dysregulation profile or a deficient emotional self-regulation (DESR) profile. Oppositional defiant disorder/conduct disorder (ODD/CD) comorbidity is prevalent in ADHD and known to be related with ED. The first-line treatment of ADHD includes psychostimulants, but their effects on ED are not well studied. This study aimed to evaluate the outcomes of methylphenidate (MPH) treatment on ED in ADHD + ODD/CD cases.
METHODS: A total of 118 ADHD + ODD/CD patients with a mean age of 9.0 ± 1.9 years were treated with MPH for 1 year. Also, parents of cases were recruited for a parent-training program, which initiated after first month of MPH treatment. Symptom severity was assessed at baseline and 12th month by Turgay Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Based Child and Adolescent Behavior Disorders Screening and Rating Scale-Parent Form, Children Depression Inventory, Child Behavior Checklist 4-18 years, and Parental Acceptance and Rejection Questionnaire-Mother Form.
RESULTS: Emotional dysregulation (DESR + DP) was present in 85.6% of cases. Conduct disorder was significantly higher in patients with DP, whereas ODD was significantly higher in the DESR and non-ED groups (P < 0.0001). Symptoms of ADHD and ED were significantly improved with 1-year of MPH treatment (P < 0.05). The improvement in ED was independent of improvement in ADHD symptoms and parent training (P < 0.05).
CONCLUSIONS: Emotional dysregulation is highly prevalent in disruptive behavioral disorders as ODD and CD, which are comorbid with ADHD. The MPH treatment is effective on ED independently from other clinical determinants.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28225747     DOI: 10.1097/JCP.0000000000000668

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  5 in total

1.  Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate Adverse Effects in a Randomized Trial of Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Tanya E Froehlich; William B Brinkman; James L Peugh; Alexandra N Piedra; Daniel J Vitucci; Jeffery N Epstein
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-12-16       Impact factor: 2.576

2.  Machine learning classification of ADHD and HC by multimodal serotonergic data.

Authors:  A Kautzky; T Vanicek; C Philippe; G S Kranz; W Wadsak; M Mitterhauser; A Hartmann; A Hahn; M Hacker; D Rujescu; S Kasper; R Lanzenberger
Journal:  Transl Psychiatry       Date:  2020-04-07       Impact factor: 6.222

3.  Effectiveness of Stimulant Medications on Disruptive Behavior and Mood Problems in Young Children.

Authors:  Ian Parsley; Zhuo Zhang; Mark Hausmann; Arica Lerdahl; Brigette Vaughan; Ryan Edwards; Soonjo Hwang
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-08-31       Impact factor: 2.582

4.  Efficacy of cognitive behavioral therapy on aggressive behavior in children with attention deficit hyperactivity disorder and emotion dysregulation: study protocol of a randomized controlled trial.

Authors:  C Vacher; L Romo; M Dereure; M Soler; M C Picot; D Purper-Ouakil
Journal:  Trials       Date:  2022-02-07       Impact factor: 2.279

5.  Methylphenidate and TBI in ADHD and co-occurring epilepsy and mental disorders: a self-controlled case series study.

Authors:  Vincent Chin-Hung Chen; Yao-Hsu Yang; Charles Tzu-Chi Lee; Yi-Lung Chen; Michael E Dewey; Michael Gossop
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-02       Impact factor: 4.785

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.